Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Cash & Equivalents: 2019-2023

Historic Cash & Equivalents for Pharming Group N.V (PHAR) over the last 2 years, with Jun 2023 value amounting to $105.0 million.

  • Pharming Group N.V's Cash & Equivalents fell 44.71% to $105.0 million in Q2 2023 from the same period last year, while for Jun 2023 it was $105.0 million, marking a year-over-year decrease of 44.71%. This contributed to the annual value of $200,391 for FY2021, which is 99.90% down from last year.
  • As of Q2 2023, Pharming Group N.V's Cash & Equivalents stood at $105.0 million, which was up 55,556.77% from $188,703 recorded in Q3 2022.
  • Pharming Group N.V's 5-year Cash & Equivalents high stood at $206.6 million for Q1 2021, and its period low was $183,324 during Q3 2021.
  • In the last 3 years, Pharming Group N.V's Cash & Equivalents had a median value of $146.7 million in 2021 and averaged $110.0 million.
  • As far as peak fluctuations go, Pharming Group N.V's Cash & Equivalents spiked by 175.94% in 2020, and later crashed by 99.91% in 2021.
  • Quarterly analysis of 5 years shows Pharming Group N.V's Cash & Equivalents stood at $74.3 million in 2019, then spiked by 175.94% to $205.2 million in 2020, then tumbled by 99.91% to $193,714 in 2021, then rose by 2.93% to $188,703 in 2022, then plummeted by 44.71% to $105.0 million in 2023.
  • Its last three reported values are $105.0 million in Q2 2023, $188,703 for Q3 2022, and $190.0 million during Q2 2022.